{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitor+%28AI%29",
    "query": {
      "intervention": "Aromatase Inhibitor (AI)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 52,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aromatase+Inhibitor+%28AI%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T14:41:08.233Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05837455",
      "title": "NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "VENTANA MIB-1 Ki67 assay",
          "type": "DEVICE"
        },
        {
          "name": "Oncotype DX® Recurrence Score",
          "type": "DEVICE"
        },
        {
          "name": "PAM50-based Prosigna breast cancer gene signature assay",
          "type": "DEVICE"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Combination anthracycline and/or taxane based treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2024-05-30",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05837455"
    },
    {
      "nct_id": "NCT01603303",
      "title": "Preventing Sexual Dysfunction With Aromatase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education Materials",
          "type": "OTHER"
        },
        {
          "name": "Luvena",
          "type": "OTHER"
        },
        {
          "name": "Hyalo-Gyn",
          "type": "OTHER"
        },
        {
          "name": "Vaginal Lubricant",
          "type": "OTHER"
        },
        {
          "name": "Interactive Internet-Based Website",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Telephone Counseling.",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 187,
      "start_date": "2012-12-05",
      "completion_date": "2017-08-11",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603303"
    },
    {
      "nct_id": "NCT05826964",
      "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "ER-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AI+CDK4/6i",
          "type": "DRUG"
        },
        {
          "name": "SERD+CDK4/6i",
          "type": "DRUG"
        },
        {
          "name": "mTOR inhibitor + AI",
          "type": "DRUG"
        },
        {
          "name": "mTOR inhibitor + SERD",
          "type": "DRUG"
        },
        {
          "name": "mTOR inhibitor + Selective estrogen receptor modulator",
          "type": "DRUG"
        },
        {
          "name": "PI3K inhibitor + SERD",
          "type": "DRUG"
        },
        {
          "name": "PI3K inhibitor + AI",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Oral SERD",
          "type": "DRUG"
        },
        {
          "name": "PARPi",
          "type": "DRUG"
        },
        {
          "name": "AKT inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Step 3 Arm 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-06-12",
      "completion_date": "2029-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05826964"
    },
    {
      "nct_id": "NCT05384119",
      "title": "Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TTI-101",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Aromatase inhibitor (AI)",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tvardi Therapeutics, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-01-09",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 6,
      "location_summary": "Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05384119"
    },
    {
      "nct_id": "NCT04176354",
      "title": "Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palbociclib + an aromatase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib + Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 813,
      "start_date": "2019-01-25",
      "completion_date": "2019-09-27",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176354"
    },
    {
      "nct_id": "NCT04498481",
      "title": "TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2018-03-01",
      "completion_date": "2018-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498481"
    },
    {
      "nct_id": "NCT01797120",
      "title": "Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PrECOG, LLC.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2013-05-31",
      "completion_date": "2017-09-12",
      "has_results": true,
      "last_update_posted_date": "2018-05-30",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 25,
      "location_summary": "Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Ames",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797120"
    },
    {
      "nct_id": "NCT05700006",
      "title": "Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Neoplasm Female",
        "Arthralgia",
        "Aging"
      ],
      "interventions": [
        {
          "name": "Aromatase inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 94,
      "start_date": "2022-07-25",
      "completion_date": "2026-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05700006"
    },
    {
      "nct_id": "NCT01153672",
      "title": "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "F-18 16 alpha-fluoroestradiol",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "RADIATION",
        "GENETIC"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2010-11",
      "completion_date": "2016-08-11",
      "has_results": true,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153672"
    },
    {
      "nct_id": "NCT01928186",
      "title": "FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Male Breast Carcinoma",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fluorothymidine F-18",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Run-in (short pre-surgery course) of endocrine-targeted therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2011-09",
      "completion_date": "2015-07-20",
      "has_results": true,
      "last_update_posted_date": "2018-05-15",
      "last_synced_at": "2026-09-26T14:41:08.233Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928186"
    }
  ]
}